ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Tuesday, November 14, 2023

2:00PM-3:30PM: Abstract Number: 2443

Blockade of OX40/OX40L Signaling Using anti-OX40L Ameliorates Systemic Lupus Erythematosus

Abstracts: SLE – Animal Models

2:00PM-3:30PM: Abstract Number: 2483

CD68 and Fibrinoid Necrosis Are Synovial Biomarkers of Severity in Early Rheumatoid Arthritis and Are Associated with a Better Response to Methotrexate: Analysis of the UCLouvain Brussels ERA Cohort

Abstracts: RA – Diagnosis, Manifestations, & Outcomes III: Predicting & Optimizing Outcomes

2:00PM-3:30PM: Abstract Number: 2436

Characterizing Spatial Organization of Immune Infiltrates in Rheumatoid Arthritis Synovia Using Spatial Transcriptomic Analysis

Abstracts: RA – Etiology & Pathogenesis

2:00PM-3:30PM: Abstract Number: 2465

Clonally Expanded B Cells in Anti-Histidyl-tRNA Synthetase Syndrome Patients Exhibit an Autoreactive-Prone Memory Phenotype and Bind Jo-1 Autoantigen

Abstracts: Muscle Biology, Myositis & Myopathies – Basic & Clinical Science I

2:00PM-3:30PM: Abstract Number: 2449

Cognitive Functioning Among Individuals with Systemic Lupus Erythematosus: A Population-Based Study

Abstracts: Epidemiology & Public Health II

2:00PM-3:30PM: Abstract Number: 2485

Comparative Risk of Serious Psychiatric Events with Belimumab versus Oral Immunosuppressant Use in Patients with Systemic Lupus Erythematosus

Abstracts: SLE – Treatment II: Nonrenal

2:00PM-3:30PM: Abstract Number: 2494

Complement mRNA Expression in Patients with ANCA-associated Glomerulonephritis

Abstracts: Vasculitis – ANCA-Associated II

2:00PM-3:30PM: Abstract Number: 2489

Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) Achievement and Sustained Response with Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in a Phase 2 Trial in SLE

Abstracts: SLE – Treatment II: Nonrenal

2:00PM-3:30PM: Abstract Number: 2435

Deciphering Rheumatoid Arthritis Disease Activity-Associated Gene Signatures and Cell Subsets Through Single Cell Transcriptomics

Abstracts: RA – Etiology & Pathogenesis

2:00PM-3:30PM: Abstract Number: 2476

Defining Cutoffs for Disease Activity States in Systemic Juvenile Idiopathic Arthritis Based on the Systemic Juvenile Arthritis Disease Activity Score

Abstracts: Pediatric Rheumatology – Clinical III: Potpourri

2:00PM-3:30PM: Abstract Number: 2480

Definition of Rheumatoid Arthritis Flare Based on SDAI and CDAI

Abstracts: RA – Diagnosis, Manifestations, & Outcomes III: Predicting & Optimizing Outcomes

2:00PM-3:30PM: Abstract Number: 2453

Development of a Hydroxychloroquine Retinopathy Prediction Score

Abstracts: Epidemiology & Public Health II

2:00PM-3:30PM: Abstract Number: 2444

Development of Engineered Smith-Specific Regulatory T Cells to Treat Lupus Nephritis

Abstracts: SLE – Animal Models

2:00PM-3:30PM: Abstract Number: 2498

Does Physical Activity Modify the Relationship Between Pain and Corticosteroid Injection Utilization in Adults with or at High Risk for Knee Osteoarthritis?

Abstracts: Interprofessional OA & Lupus

2:00PM-3:30PM: Abstract Number: 2478

Effect of Conventional and Biologic Disease-Modifying Anti-Rheumatic Drugs on the Antibody Response to Four Doses of COVID-19 mRNA Vaccines in Children with Autoimmune and Rheumatic Diseases

Abstracts: Pediatric Rheumatology – Clinical III: Potpourri

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].